RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-09-29 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-09-30 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 2 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-Q · filed 2026-08-06 | |||||||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-07 | |||||||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-12 | |||||||
| 2024-12-31 | 0.00% 10-K · filed 2025-03-27 | |||||||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-07 | |||||||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-07 | |||||||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-27 | |||||||
| 2023-09-18 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-08 | |||||||
| 2022-12-21 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2022-09-29 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2022-03-28 | 0.00% 10-Q · filed 2022-05-05 | 0.00% 10-K · filed 2024-03-19 | 0.00% 10-K · filed 2023-03-23 | |||||
| 2022-03-14 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2022-01-01 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2021-12-31 | 0.00% 10-K · filed 2022-03-25 | |||||||
| 2021-12-22 | 0.00% 10-K · filed 2024-03-19 | |||||||
| 2021-12-17 | 0.00% 10-K · filed 2024-03-19 | 0.00% 10-K · filed 2023-03-23 | ||||||
| 2021-07-16 | 0.00% 10-Q · filed 2021-11-12 | |||||||
| 2021-07-12 | 0.00% 10-Q · filed 2021-11-12 | |||||||
| 2021-06-25 | 0.00% 10-Q · filed 2021-08-10 | 0.00% 10-Q · filed 2021-11-12 | ||||||
| 2021-06-18 | 0.00% 10-Q · filed 2021-08-10 | 0.00% 10-Q · filed 2021-11-12 | ||||||
| 2021-02-18 | 0.00% 10-K · filed 2023-03-23 | |||||||
| 2021-01-06 | 0.00% 10-K · filed 2023-03-23 | |||||||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-25 | |||||||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-24 | 0.00% 10-K · filed 2021-03-24 | ||||||
| 2019-06-30 | 0.00% 10-K · filed 2021-03-24 | |||||||
| 2018-03-31 | 0.00% 10-Q · filed 2018-05-14 | |||||||
| 2017-12-31 | 0.00% 10-Q · filed 2018-02-12 | |||||||
| 2017-09-30 | 0.00% 10-Q · filed 2017-11-14 | |||||||
| 2016-06-30 | 0.00% 10-K · filed 2016-09-09 | |||||||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-15 | |||||||
| 2015-12-31 | 0.00% 10-Q · filed 2017-02-10 | |||||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-10 | |||||||
| 2015-06-30 | 0.00% 10-K · filed 2016-09-09 | |||||||
| 2015-03-31 | 0.00% 10-Q · filed 2015-05-15 | 0.00% 10-Q · filed 2016-05-09 | ||||||
| 2014-12-31 | 0.00% 10-Q · filed 2015-02-13 | 0.00% 10-Q · filed 2016-02-05 | ||||||
| 2014-09-30 | 0.00% 10-Q · filed 2015-11-06 | |||||||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-15 | 0.00% 10-Q · filed 2015-05-15 | ||||||
| 2013-12-31 | 0.00% 10-Q · filed 2015-02-13 | 0.00% 10-Q · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |